This article is more than 5 years old. Information may no longer be current.
VIDEO: Adalimumab appears effective in non-radiographic axial spondyloarthropathy
Click Here to Manage Email Alerts
SAN DIEGO – Treatment with adalimumab led to remission and sustained disease control among patients with non-radiographic axial spondyloarthropathy, according to findings presented at the American College of Rheumatology Annual Meeting.
In addition, patients receiving placebo in a later part of the trial experienced disease flares, “which suggests that this population of patients doesn’t have transient disease,” according to Eric M. Ruderman, MD, professor of medicine at Northwestern University’s Feinberg School of Medicine.
“That’s a question that we’ve been looking at for quite some time – is this a chronic issue or do these people have a transient disease that may just get better spontaneously?” Ruderman said. “The data from this trial would suggest that’s not the case.”
Reference:
Landewé RBM, et al. Abstract 1787. Presented at: ACR Annual Meeting; Nov. 3-8, 2017; San Diego.